Literature DB >> 8946206

Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer.

A Komiya1, H Suzuki, T Ueda, R Yatani, M Emi, H Ito, J Shimazaki.   

Abstract

DNA samples from tumors and paired normal tissues from 48 patients with prostate cancer (stage B, 16 cases; stage C, 14 cases; stage D, 18 cases) were examined with 26 polymorphic markers spanning chromosome 10. Allelic losses were observed in 17 of the 46 cases (37%) that were informative with at least one of the markers. Detailed deletion mapping identified two distict commonly deleted regions on the long arm of chromosome 10 (10q22-q24:7 cM and 10q25.1:17 cM) and one on 10p, suggesting that at least three tumor suppressor genes associated with prostate cancer are present on this chromosome. We observed loss of heterozygosity more frequently in tumors from fatal cases (stage D, 8/16, 50%) than in localized tumors (stage B, 0/16, 0%; P = 0.001 or stage B + C, 5/30, 17%; P = 0.02 Fisher's exact test). All metastatic tissues showed allelic loss at one or more loci on 10q. In five of the nine patients from whom DNAs were available from both metastatic and primary tumors, the primary cancer foci had no detectable abnormality of chromosome 10, while the metastatic foci showed allelic loss on chromosome 10. These results suggested that inactivation of one or more tumor suppressor genes on chromosome 10 plays an important role in late stages of prostate cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8946206     DOI: 10.1002/(SICI)1098-2264(199612)17:4<245::AID-GCC6>3.0.CO;2-3

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

1.  Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage.

Authors:  Jianfeng Xu; Carl D Langefeld; S Lilly Zheng; Elizabeth M Gillanders; Bao-Li Chang; Sarah D Isaacs; Adrienne H Williams; Kathy E Wiley; Latchezar Dimitrov; Deborah A Meyers; Patrick C Walsh; Jeffrey M Trent; William B Isaacs
Journal:  Hum Genet       Date:  2004-06-05       Impact factor: 4.132

2.  Genomewide scan for prostate cancer-aggressiveness loci.

Authors:  J S Witte; K A Goddard; D V Conti; R C Elston; J Lin; B K Suarez; K W Broman; J K Burmester; J L Weber; W J Catalona
Journal:  Am J Hum Genet       Date:  2000-05-24       Impact factor: 11.025

3.  Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma.

Authors:  J A Macoska; J Xu; D Ziemnicka; T S Schwab; M A Rubin; L Kotula
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

4.  Cytogenetic analyses of secondary liver tumors reveal significant differences in genomic imbalances between primary and metastatic colon carcinomas.

Authors:  L A Parada; A Marañon; M Hallén; K G Tranberg; U Stenram; G Bardi; B Johansson
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

5.  Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Authors:  Weisheng Zhang; Brian B Haines; Clay Efferson; Joe Zhu; Chris Ware; Kaiko Kunii; Jennifer Tammam; Minilik Angagaw; Marlene C Hinton; Heike Keilhack; Cloud P Paweletz; Theresa Zhang; Chris Winter; Sriram Sathyanarayanan; Jonathan Cheng; Leigh Zawel; Stephen Fawell; Gary Gilliland; Pradip K Majumder
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 6.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

7.  In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.

Authors:  G P Robertson; F B Furnari; M E Miele; M J Glendening; D R Welch; J W Fountain; T G Lugo; H J Huang; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Deletion, mutation, and loss of expression of KLF6 in human prostate cancer.

Authors:  Ceshi Chen; Eija-Riitta Hyytinen; Xiaodong Sun; Heikki J Helin; Pasi A Koivisto; Henry F Frierson; Robert L Vessella; Jin-Tang Dong
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

9.  Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.

Authors:  Rachel M Squillace; David Miller; Scott D Wardwell; Frank Wang; Tim Clackson; Victor M Rivera
Journal:  Int J Oncol       Date:  2012-05-18       Impact factor: 5.650

10.  Landscape of chromosome number changes in prostate cancer progression.

Authors:  Martin Braun; Julia Stomper; Robert Kirsten; David Adler; Wenzel Vogel; Diana Böhm; Nicolas Wernert; Glen Kristiansen; Sven Perner
Journal:  World J Urol       Date:  2013-03-20       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.